The influenza virus M2 protein is a well-validated yet underexploited proton-selective ion channel essential for influenza virus infectivity. Because M2 is a toxic viral ion channel, existing M2 inhibitors have been discovered through live virus inhibition or medicinal chemistry rather than M2-targeted high-throughput screening (HTS), and direct measurement of its activity has been limited to live cells or reconstituted lipid bilayers. Here, we describe a cell-free ion channel assay in which M2 ion channels are incorporated into virus-like particles (VLPs) and proton conductance is measured directly across the viral lipid bilayer, detecting changes in membrane potential, ion permeability, and ion channel function. Using this approach in high-throughput screening of over 100,000 compounds, we identified 19 M2-specific inhibitors, including two novel chemical scaffolds that inhibit both M2 function and influenza virus infectivity. Counterscreening for nonspecific disruption of viral bilayer ion permeability also identified a broad-spectrum antiviral compound that acts by disrupting the integrity of the viral membrane. In addition to its application to M2 and potentially other ion channels, this technology enables direct measurement of the electrochemical and biophysical characteristics of viral membranes.
T he M2 gene of influenza virus encodes a 97-amino-acid, homotetrameric, proton-selective ion channel necessary for influenza virus infectivity (1, 2) . Activation of M2 is triggered by low pH in host cell endosomes, resulting in an influx of protons into the virus and acidification that releases the viral RNA into the host cell (2) (3) (4) . M2 also helps to package viral RNA (5, 6) and regulate pH in the Golgi apparatus of infected cells during viral assembly (7) . Two FDA-approved adamantane-based drugs, amantadine and rimantadine (2, 8) , are potent M2 inhibitors that can neutralize influenza virus in humans and other animals. However, the emergence of widespread highly virulent adamantane-resistant strains such as avian and swine influenza virus strains (9, 10) has prompted the need for newer antivirals. Drug discovery efforts targeting M2 have been difficult due to the toxicity of M2 in cells (11) , the difficulty of reconstituting M2 in liposomes for largescale application (12, 13) , and the labor-intensive, low-throughput electrophysiological approaches typically used to study ion channels.
To address these challenges, we developed a rapid, cell-free assay to measure the movement of proton ions directly across the lipid bilayer of virus-like particles (VLPs). High-throughput screening (HTS) of M2-VLPs using Ͼ100,000 compounds identified 19 M2-specific inhibitors, including two novel chemical scaffolds, that inhibited both M2 function and influenza virus infectivity. Counterscreening for nonspecific disruption of carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) protonophore activity also identified a broad-spectrum antiviral compound that acts by disrupting the integrity of the viral membrane but that is not toxic to cells. In addition to its application to M2 and potentially other ion channels, this technology enables measurement of the electrochemical and biophysical characteristics of viral membranes. Chemical libraries. Small-molecule screening was carried out inhouse and at the National Screening Laboratory for the Regional Centers of Excellence in Biodefense and Emerging Infectious Disease (NSRB) at the ICCB-Longwood Screening Facility, Harvard Medical School, Boston, MA. Combinatorial libraries containing 107,572 compounds (Enamine, MayBridge, Life Chemicals, ChemDiv, Prestwick, Bionet, Microsource Discovery System, and TimTec) were used at final concentrations of 5 to 15 M. For validation studies, a chemical compound library containing 71 known ion channel ligands (Biomol International, Farmingdale, NY) was used at a final concentration of 20 M. All compounds were resuspended in 100% dimethyl sulfoxide (DMSO).
MATERIALS AND METHODS

Plasmid
M2 VLP production. VLPs containing M2 ("lipoparticles") were produced by cotransfection of HEK-293T cells with plasmids carrying the M2 gene and the retroviral (murine leukemia virus [MLV]) Gag protein, as previously described (14, 15) . Null-VLPs (without M2) were produced by transfection of HEK-293T cells with the Gag plasmid alone. Mock particle preparations (M2 without Gag) were produced by transfection of HEK-293T cells with the M2 plasmid alone. Forty-eight hours after transfection, supernatants containing VLPs were harvested, passed through a 0.45-m filter, centrifuged through a 20% sucrose cushion or a 10 to 30% OptiPrep (Sigma, St. Louis, MO) density gradient, and resuspended in 10 mM HEPES, pH 7.5. Each batch of VLPs produced was assayed for homoge-neity by dynamic light scattering (DLS) using a Proterion DynaPro DLS and for total protein concentration by bicinchoninic acid (BCA) protein assay reagent (Thermo Scientific, Waltham, MA). The incorporation of M2 proteins in VLPs was detected by Western blotting using an antibody against a C-terminal V5 epitope tag (Life Technologies, Carlsbad, CA). M2-VLPs were imaged by transmission electron microscopy (EM) at the Fox Chase Cancer Center microscopy core facility (Philadelphia, PA).
M2-VLP screening. Compounds were screened against the HK/156/ 1997 strain of M2-VLPs and counterscreened against Null-VLPs treated with 5 M FCCP [carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone] (Sigma, St. Louis, MO) in 384-well plates. VLPs were suspended in 10 mM HEPES, pH 7.0, 150 mM NaCl buffer supplemented with 1% FMP-Blue dye (Molecular Devices, Sunnyvale, CA). One microgram of M2-VLPs was dispensed into 384-well black clear-bottom plates (Costar 3712; Corning, NY) and preincubated for 1 h at room temperature with 100 nl of each compound delivered by pin tool (V&P Scientific, San Diego, CA). Baseline fluorescence measurements (excitation, 530/emission, 565) were acquired using a fluorescence plate reader (Molecular Devices FlexStation II or PerkinElmer Envision II). Ten microliters of 150 mM MES [2-(N-morpholino)ethanesulfonic acid] (Sigma, St. Louis, MO), pH 4.5 ("low-pH buffer"), was injected into each well followed by fluorescence measurements. Using the FlexStation reader, fluorescence was measured every 2.5 s for 150 s. Using the Envision reader, single baseline and endpoint measurements were obtained. All screening values were baseline subtracted, and the maximum signal was normalized to a no-compound control. Cherry-picked compounds were rescreened prior to further characterization. Dose-response data were fitted using nonlinear regression in GraphPad Prism.
Cytotoxicity assay. Cells were passaged in Dulbecco's modified Eagle's medium (DMEM) containing glutamine, penicillin, and streptomycin (100 g/ml) supplemented with 10% fetal bovine serum (FBS 5 cells/well) and incubated overnight at 37°C, 5% CO 2 . The next day, purified Udorn/307/1972 virus was diluted in DMEM supplemented with 1 g/ml tosylsulfonyl phenylalanyl chloromethyl ketone (TPCK)-treated trypsin and 0.3% bovine serum albumin (BSA) to a multiplicity of infection (MOI) of 0.0001. Diluted virus was either added directly to cells followed immediately by the addition of compound or preincubated with compound at room temperature for 1 h prior to infection. Cells were incubated with the virus and compound mixtures at 37°C for 1 h. Subsequently, medium containing virus and compound was removed, and cells were washed once with PBS and layered with 1.8% agar either with or without compound in minimal essential medium (MEM) and 2 g/ml TPCK trypsin. Cells were incubated at 37°C for an additional 48 h to develop plaques. Cells were then stained with 0.1% crystal violet in 10% formaldehyde for 5 min and washed three times with water. The total number of plaques was counted for each well, and the activity of each compound was expressed as a percentage of control in the absence of drug.
Reporter virus infectivity assays. Infections were carried out in a 96-well plate using HIV and vesicular stomatitis virus (VSV) envelope reporter viruses (pseudotyped onto an HIV reporter backbone), and dengue reporter viruses (16) 
RESULTS
Incorporation of M2 ion channels into VLPs.
Retroviral virus particles and virus-like particles (VLPs) are similarly formed by the budding of retroviral Gag through the plasma membrane of cells and have been shown to incorporate complex membrane proteins without the use of detergents or protein purification (14, 15, 17, 18) . Because membrane proteins incorporated into VLPs have proven structurally intact when tested against conformational antibodies and ligands (14, 15, 17, 18) , we reasoned that isolated ion channels such as M2 may also be functional if they could be incorporated and measured. VLPs that contain high concentrations of the M2 ion channel protein were produced. M2-VLPs contain a noninfectious retroviral (MLV) Gag core surrounded by a host cell-derived lipid membrane containing high concentrations of incorporated M2 protein. M2-VLPs, produced and purified as described previously (14, 15, 19) , showed high purity and homogeneity, low polydispersity (4.9%), and a hydrodynamic diameter of ϳ250 nm, similar to other purified VLPs (Fig. 1a) . Purified VLPs imaged by electron microscopy (EM) were consistent with these measurements (Fig. 1a, inset) .
We produced VLPs containing M2 ion channels from diverse strains of influenza virus, including Udorn/307/1972, B/Lee/40, and HK/156/1997 (Fig. 1b) , as well as HK/1073/1999, PR/8/1934, and VN/1194/2004 (not shown). To confirm M2 incorporation, purified M2-VLPs were run on an SDS-PAGE gel and probed with an antibody against a C-terminal V5 epitope tag on each M2 protein. A major band at ϳ15 kDa demonstrates the presence of monomeric M2 protein for each strain. Density gradient purification of M2-VLPs resulted in cofractionation of virion particles, retro- viral Gag, and M2 activity ( Fig. 1c and d) . Taken together, these results demonstrate that full-length M2 from various strains of influenza virus can be successfully incorporated into highly purified preparations of VLPs.
Activation of M2-VLPs. Upon exposure to low pH in the endosome, M2 mediates an influx of protons that both depolarizes the influenza virus membrane and lowers the pH of the virion interior (1, 2). To detect a membrane potential change directly across the VLP membrane, we used a potentiometric fluorescent dye (FMP [FLIPR membrane potential dye]; Molecular Devices) (Fig. 2a) , which fluoresces more brightly upon membrane depolarization (20) . Challenge of M2-VLPs with an acidic buffer (pH 4.5) resulted in increased M2-specific fluorescence (Fig. 2b) . No membrane depolarization was detected upon pH challenge of Null-VLPs (without M2), indicating the necessity of M2 for depolarization. Proton-driven membrane depolarization could also be mediated when the proton ionophore FCCP (21) was added to Null-VLPs prior to pH challenge. Importantly, M2 inhibitors amantadine (100 M) and rimantadine (10 M) completely abrogated ion conductance in M2-VLPs but had no effect on FCCPtreated VLPs.
M2-VLPs containing M2 proteins from diverse influenza virus strains demonstrated robust depolarization in response to pH challenge (Fig. 2c) . Mock VLP preparations from cells transfected with M2 but without Gag did not show activity, indicating that true VLPs rather than M2-induced membrane blebs (22) were responsible for the observed changes in membrane potential. Taken together, these data demonstrate the functionality of M2 ion channels in VLPs and validate their utility as a noninfectious, cell-free, in vitro biochemical platform capable of assessing M2 ion channel activity. The ability of VLPs to maintain a membrane potential also demonstrates for the first time that lipid viral membranes are structurally intact and impermeable to ions, a matter of previous uncertainty (23) , and offers the possibility that membrane potential itself, rather than just pH changes, could play a role in some parts of the virus life cycle (24, 25) .
Validation of M2-VLP activity measurements. To further measure the native functionality of M2 in VLPs, dose-response curves were generated with amantadine and rimantadine, with full inhibition of the M2 signal observed with high concentrations of drug (Fig. 3a) . Fifty percent inhibitory concentrations (IC 50 s) of 0.5 to 2 M for amantadine and 0.1 to 0.6 M for rimantadine were calculated (depending on the experiment), comparable to published values of M2 ion channel inhibition by electrophysiology (46) and influenza virus inhibition in tissue culture (26, 27) . Inhibitory effects were specific to the M2 ion channel, since even the highest drug concentrations tested did not abrogate signals mediated by the protonophore FCCP. Importantly, amantadine did not inhibit M2 variants derived from known amantadine-resistant strains PR/8/1934, VN/1194/2004, and B/Lee/40 (Fig. 3b) .
For many strains of influenza virus, sensitivity to adamantane a Screening metrics for the M2-VLP assay using seven different variants of M2 and FCCP-VLPs. Each VLP variant was screened in at least two separate experiments against a smallscale library of 71 known ion channel inhibitors (BioMol ion channel library), along with 6 positive (uninhibited) controls and 4 negative controls. Average screening metrics for each strain are shown, including % coefficient of variation (CV) of the positive controls, signal-to-noise ratio [(mean signal Ϫ mean background)/(standard deviation of background)], signal-to-background ratio (mean signal/mean background), and the estimated Z= factor. The Z= factor was calculated using 100 M amantadine controls for adamantane-sensitive strains and Null-VLP controls for adamantane-resistant strains and FCCP-VLPs. NA, not applicable. Broad-spectrum, membraneactive inhibitor compounds has been mapped to specific amino acids. Mutation S31N, and to a lesser extent V27A, is found in clinical strains of influenza virus which are insensitive to adamantanes (2, 28) . To establish whether these mutations would cause a similar resistant phenotype in M2-VLPs, we introduced the S31N point mutation into M2 of the amantadine-sensitive strain Udorn/307/1972 and demonstrated that the mutation conferred complete drug resistance (Fig. 3c) . Conversely, the incorporation of the sensitizing mutations A27V and N31S was sufficient to confer amantadine sensitivity on M2-VLPs based on PR/8/1934, a normally resistant strain. The strict correlation between characterized influenza virus M2 genotypes and drug sensitivity phenotypes in M2-VLPs suggests that the in vitro M2-VLP assay can be used to monitor the inhibition of M2 function from diverse strains of influenza virus. High-throughput screening using M2-VLPs. We next adapted the M2-VLP assay to a 384-well microplate format to enable the screening of large compound libraries for inhibitory activity against M2. Upon pH challenge, we observed a clear separation of M2-dependent signal between control and amantadineinhibited signal with a Z= of Ͼ0.5 using seven different M2-VLP variants, indicating high sensitivity, low variability, and suitability of this assay for high-throughput screening ( Fig. 4a and Table 1) . We also developed a novel counterscreen using Null-VLPs incubated with the FCCP protonophore to identify compounds that nonspecifically inhibit membrane potential across the viral lipid bilayer. Using these screens, amantadine and rimantadine were reliably identified as hits against M2-VLPs (Fig. 4b) . As a proof of concept, we screened a 71-compound library of known ion channel inhibitors against seven different M2 variants and against FCCP-treated Null-VLPs (Fig. 4c and Table 1) , and amantadine was again identified as a specific hit in all screens against adamantane-sensitive M2 strains but not in screens against resistant strains.
To identify novel inhibitors of influenza virus M2, we screened 107,572 compounds using M2-VLPs. We focused on the adamantane-sensitive strain HK/156/1997 for screening so that rimantadine could serve as an internal positive control. Each compound was screened at least once for activity against M2-VLPs and for lack of activity against FCCP-treated Null-VLPs. The top ϳ400 compounds showing the highest levels of inhibition against M2-VLPs and low inhibitory activity against FCCP-treated Null-VLPs were classified as primary hits and rescreened to confirm specific activity. Following confirmation and secondary screening, 19 compounds were classified as validated hits with potent in vitro IC 50 s (140 nM to ϳ13 M), little or no toxicity at concentrations of 40 M (ϳ3-to 300-fold above their calculated in vitro IC 50 s), and activity against live influenza virus (Udorn/307/1972), with many compounds demonstrating potent antiviral effects similar to those of amantadine and rimantadine (Table 2) .
Structural analysis of validated M2 hits revealed compounds with varied chemical scaffolds. We identified two novel scaffolds based on a bicyclic structure (compounds 5 and 6) that inhibited both M2 in vitro and live influenza virus without cellular toxicity. Two additional compounds (compounds 3 and 4) contained a scaffold recently reported to have anti-influenza virus activity (29) . Other validated hits comprised a structurally related family of compounds containing an adamantane ring (compounds 7 to 21). Although all of these compounds were active against the adamantane-sensitive strains HK/156/1997 and Udorn/307/1972, they did not exhibit activity against the adamantane-resistant strain VN/1194/2004, PR/8/1934, or B/Lee/40, or against an adamantane-resistant mutant, Udorn/307/1972 V27A, at concentrations up to 100 M (Fig. 5) , consistent with the use of an adamantane-sensitive strain in our screening strategy. Using medicinal chemistry and computational predictions (although not highthroughput screening), 10 nonadamantane scaffolds active against influenza virus M2 have been reported in recent years, none of which inhibit the ubiquitous S31N amantadine-resistant mutant (29) (30) (31) (32) (33) (34) . Recently, however, amantadine-based compounds have been further derivatized to create variants that can inhibit wild-type and S31N resistant strains (35, 36) . Our ion channel VLP technology complements these efforts, and our results suggest that future screening efforts using a resistant strain for primary screening should identify novel, non-adamantanebased compounds capable of inhibiting adamantane-resistant viruses.
Identification of broad-spectrum membrane-active compounds. In addition to M2-specific inhibitors, our screening also identified a second group of "membrane-active" compounds which disrupted both M2-and FCCP-mediated viral membrane potential. Characterization of one of these compounds ( Table 2 , compound 22) revealed potent inhibition of M2-VLPs, FCCPVLPs, and live influenza virus, with IC 50 s between 1 and 5 M (Fig. 6) . Inhibitory activity against FCCP-treated VLPs suggests that this compound has a broad mechanism of action that disrupts the integrity of viral membranes. To test this, we assessed its inhibition against a panel of diverse reporter viruses, including HIV, dengue virus (DENV), and vesicular stomatitis virus (VSV). Remarkably, this compound inhibited the infectivity of each virus tested, with no significant toxicity for a number of target cell types. Together, these data suggest that this compound has a broadspectrum mechanism of action that specifically disrupts viral membranes while sparing cellular membranes. During the course of our studies, a related compound was identified and characterized by others as a broad-spectrum compound that irreparably damages viral membranes (37, 38) , corroborating our data and validating the utility of our counterscreening approach for discovering broad-spectrum viral inhibitors. 
DISCUSSION
Influenza virus continues to be a major global disease that claims hundreds of thousands of lives each year and threatens to become a major global pandemic with the emergence of highly virulent and drug-resistant strains. The M2-VLP assay described here provides a safe, rapid, and robust biochemical format for discovering novel influenza virus inhibitors using cell-free HTS campaigns. Our work also provides, to the best of our knowledge, the first measurements of membrane potential directly across viral membranes and the first evidence that viral membranes are impermeable to ions and so may enable a better understanding of the electrochemical and biophysical properties of viral membranes (19, 24, 25, 39) , which have been underexplored areas of virology.
The technology described here may also provide a strategy for studying other viral and even cellular ion channels which may be toxic in live cells. Despite their biomedical significance, ion channels in general remain resistant to many traditional modes of manipulation and functional detection, in large part because their activity is often difficult to study outside living cells and in traditional high-throughput screening formats. Assays for ion channel activity usually require living cells because the cell membrane both maintains ion channel structure and forms the electrochemical barrier required for electrical signals. However, cells possess inherent limitations in size and environmental requirements, and many ion channels are inherently toxic or poorly expressed. As a result, traditional methods of discovering ion channel drugs have been very difficult. High-throughput patch-clamp techniques have accelerated electrophysiological studies of ion channels (40, 41) but remain expensive, require specialized machinery, and are not as fast as traditional fluorescent or luminescent microplate detection approaches.
Previous studies of M2 within virus particles have used indirect measurements of viral ion channel activity, such as fluorescent dye dissipation upon fusion (39) . Using the technology described here, toxic ion channels can be tested, and the size of VLPs (ϳ150 nm) permits ion channel activity screening to be miniaturized for microwell, microarray, or microfluidic applications that often cannot support live cells. Fluorescent probes that respond to changes in electrical membrane potential have been well described (20, 42, 43, and 44) , but the dyes are typically toxic at high concentrations and partition into cell organelle structures that increase background and nonspecific artifacts (43, 45) . Our use of membrane potential dyes within VLPs, however, avoids the limitations of living cells.
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